Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is building a catheter-based therapy designed to reduce hunger signals by targeting branches of the vagus nerve associated with appetite regulation. Its treatment approach is intended to function as a one-time outpatient intervention performed in a procedure similar to gastroscopy, without requiring implants or long-term medication use. Sedivention’s platform includes proprietary cryo-balloon catheter technology and related medical devices for interventional obesity care. The company conducts product development, preclinical validation, and clinical preparation activities focused on gastrointestinal and metabolic health applications. Its technology is designed to support obesity management by addressing physiological mechanisms related to hunger and satiety regulation.